Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma

Clinical trial NCT01870726 · TERMINATED

Trial details

NCT number: NCT01870726
Sponsor: Novartis Pharmaceuticals
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM

Start date: 2014-01-09
Primary completion: 2016-12-23
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.